Hormones, Receptors, GPCRs and Second Messengers
Signalling modes, nuclear and surface receptors, GPCRs, cAMP, IP3/DAG, Ca2+, cGMP, RTK-Ras-MAPK, PI3K-Akt, JAK-STAT and receptor binding for CSIR NET.
- 22 min
On this page · 15 sections
- Prerequisites
- The Hook: A Hormone That Never Enters the Cell
- Modes of Cell Signalling
- Receptor Binding: Numbers You Must Handle
- The Receptor Families
- G-Protein-Coupled Receptors
- Second Messengers
- Enzyme-Coupled Receptors
- Memory Tricks
- Don’t Confuse
- Common Mistakes
- Practice
- Quick Revision Table
- Key Takeaways
- What’s Next
Prerequisites
- Membranes, Transport and Electrical Properties — receptors sit in the bilayer; ion channels and pumps set the Ca²⁺ and voltage gradients that signals exploit.
- Enzymes: Catalysis, Kinetics, Regulation and Isozymes — allostery, phosphorylation and the hyperbolic binding curve reused here for receptor occupancy.
- Endocrinology and Reproduction — which gland makes which hormone; this page explains how the target cell hears it.
The Hook: A Hormone That Never Enters the Cell
How CSIR NET asks it. Part B: which G protein couples to which effector, what cholera and pertussis toxins do, which second messenger comes from which enzyme, SH2 and PH domains, Ras GEF vs GAP. Part C: experiments with toxins, forskolin, PDE inhibitors, dominant-negative or constitutively active mutants; Scatchard plots; spare-receptor arithmetic; ordering a pathway from epistasis data.
Modes of Cell Signalling
| Mode | Signal travels | Example |
|---|---|---|
| Endocrine | Through the blood to distant targets | Insulin, adrenaline, thyroxine |
| Paracrine | Short distance in tissue fluid to neighbours | Growth factors, NO in blood vessels, morphogens |
| Autocrine | Back to the secreting cell (or cells of the same type) | IL-2 on activated T cells; some tumour growth factors |
| Contact-dependent (juxtacrine) | Membrane-bound ligand on one cell, receptor on the touching cell | Delta–Notch |
| Synaptic | Neurotransmitter across a synaptic cleft | Acetylcholine at the neuromuscular junction |
The same molecule can act in more than one mode (adrenaline is a hormone and a neurotransmitter). What makes a cell respond is the receptor, and the response depends on the cell: acetylcholine slows heart muscle (muscarinic M2), contracts skeletal muscle (nicotinic) and stimulates secretion in salivary glands (muscarinic M3).
Hormones by chemistry and where their receptors are
| Class | Examples | Solubility | Receptor location | Typical speed |
|---|---|---|---|---|
| Peptides and proteins | Insulin, glucagon, growth hormone, ADH | Water-soluble | Cell surface | Seconds to minutes |
| Amines (catecholamines) | Adrenaline, noradrenaline, dopamine | Water-soluble | Cell surface | Seconds |
| Amine (thyroid) | Thyroxine (T₄), triiodothyronine (T₃) | Lipophilic (carried on proteins) | Nuclear | Hours |
| Steroids | Cortisol, aldosterone, oestradiol, testosterone, calcitriol | Lipophilic | Intracellular (cytoplasm or nucleus) | Hours |
| Retinoids | Retinoic acid | Lipophilic | Nuclear | Hours |
| Eicosanoids | Prostaglandins, thromboxanes, leukotrienes | Lipid, local | Cell surface (GPCRs) | Seconds to minutes |
| Gases | NO | Diffuses through membranes | Intracellular enzyme (soluble guanylyl cyclase) | Seconds |
Receptor Binding: Numbers You Must Handle
Ligand binding to a single class of independent sites follows the same hyperbola as Michaelis–Menten kinetics:
$$B = \frac{B_{max}[L]}{K_d + [L]}, \qquad \text{fractional occupancy } \theta = \frac{[L]}{K_d + [L]}$$- At \([L] = K_d\), half the receptors are occupied. At \([L] = 3K_d\), 75%; at \(9K_d\), 90%.
- \(K_d\) is a dissociation constant (concentration units). Smaller \(K_d\) = higher affinity. Typical hormone receptors have \(K_d\) in the nM range or below, matching the low circulating hormone concentration.
Scatchard plot. Rearranging gives
$$\frac{B}{F} = \frac{B_{max} - B}{K_d}$$Plot bound/free (y) against bound (x): a straight line of slope \(-1/K_d\) and x-intercept \(B_{max}\). A curved (concave-up) Scatchard plot indicates two classes of sites or negative cooperativity.
Spare receptors. In many cells the maximal response is reached when only a fraction of receptors is occupied (insulin acting on adipocytes is the usual textbook case). Then the concentration giving half-maximal response (EC₅₀) is lower than \(K_d\). Removing some receptors (or blocking them irreversibly) first shifts the dose–response curve to the right and only later lowers the maximum.
Specificity, amplification, desensitisation, integration. These four words describe every pathway below. Amplification comes from enzymes in series (one active receptor activates many G proteins; one adenylyl cyclase makes many cAMP; one protein kinase phosphorylates many targets). Desensitisation (adaptation) lets a cell respond to a change in signal rather than its absolute level.
The Receptor Families
graph TD
S["Extracellular signal"] --> L{"Can it cross
the membrane?"}
L -- "Yes: steroids, T3,
retinoids, NO" --> I["Intracellular receptor
nuclear receptor or soluble GC"]
L -- "No: peptides, amines,
most others" --> C["Cell-surface receptor"]
C --> IC["Ion-channel-coupled
nicotinic AChR, GABA-A"]
C --> G["G-protein-coupled
7 transmembrane helices"]
C --> E["Enzyme-coupled
RTK, TGF-beta receptor,
receptor guanylyl cyclase"]
C --> K["Kinase-associated
cytokine receptors + JAK"]
C --> P["Proteolysis-dependent
Notch, Wnt, Hedgehog, NF-kB"]Nuclear (intracellular) receptors
The nuclear receptor superfamily are ligand-regulated transcription factors with a common plan: an N-terminal activation region, a central DNA-binding domain with two zinc fingers, a hinge, and a C-terminal ligand-binding domain that also carries a ligand-dependent activation function.
| Feature | Steroid receptors (GR, MR, PR, AR, ER) | TR, RAR, VDR group |
|---|---|---|
| Location without hormone | Often cytoplasmic (GR is held by Hsp90 and chaperones) | Nuclear, already on DNA |
| Partner on DNA | Homodimers | Heterodimers with RXR |
| Without ligand | Inactive, away from DNA | Bound to DNA with co-repressors (histone deacetylase complexes) that silence the gene |
| Ligand binding | Releases chaperones; receptor dimerises, enters nucleus, binds hormone response element | Swaps co-repressor for co-activator (with histone acetyltransferase activity) |
The DNA sequence bound is a hormone response element (HRE), often a pair of six-base half-sites. Steroid responses are slow (hours) because they need transcription and translation, and they often come in two waves: a primary response of a few genes directly induced, then a secondary response driven by the proteins of the primary genes. Cycloheximide blocks the secondary but not the primary transcriptional response.
Ion-channel-coupled receptors
Ligand-gated channels convert binding directly into an ion flux in milliseconds: nicotinic acetylcholine receptor, GABA-A, glycine, ionotropic glutamate (AMPA, NMDA, kainate) and 5-HT₃ receptors. They are treated with neurotransmission in Adhesion, Junctions, ECM, Neurotransmission and Haematopoiesis.
G-Protein-Coupled Receptors
GPCRs are the largest family of cell-surface receptors in animals. Each is a single polypeptide that crosses the membrane seven times (N-terminus outside, C-terminus inside). Ligands range from photons (rhodopsin) and odorants to amines, peptides, lipids and proteases (protease-activated receptors are activated by cleavage of their own N-terminus). A large share of approved drugs target GPCRs.
The heterotrimeric G-protein cycle
G proteins are trimers of Gα (binds GDP/GTP, has GTPase activity), Gβ and Gγ (Gβγ is a tight dimer; both Gα and Gγ are lipid-anchored).
- Resting: Gα·GDP bound to Gβγ.
- Activation: ligand-bound receptor acts as a GEF (guanine-nucleotide exchange factor): it opens Gα so GDP leaves and GTP (abundant in cytosol) enters.
- Dissociation/rearrangement: Gα·GTP separates from Gβγ; both can regulate effectors.
- Switch-off: Gα hydrolyses its GTP. RGS proteins (regulators of G-protein signalling) act as GAPs for Gα and speed this up. Gα·GDP reassociates with Gβγ.
One active receptor can activate many G proteins before it is switched off, the first stage of amplification.
| Gα family | Main effector | Second messenger change | Example receptors |
|---|---|---|---|
| Gs | Adenylyl cyclase ↑ | cAMP ↑ | β-adrenergic, glucagon, ADH (V2, kidney), TSH, FSH/LH, histamine H2 |
| Gi | Adenylyl cyclase ↓; Gβγ opens GIRK K⁺ channels | cAMP ↓; hyperpolarisation | α2-adrenergic, muscarinic M2 (heart), opioid, GABA-B |
| Gq | Phospholipase Cβ ↑ | IP₃ and DAG ↑, Ca²⁺ ↑ | α1-adrenergic, muscarinic M1/M3, ADH (V1, vessels), angiotensin II (AT1), histamine H1 |
| G12/13 | RhoGEFs → Rho | Cytoskeletal change | Thrombin (PAR), LPA |
| Gt (transducin) | cGMP phosphodiesterase (PDE6) ↑ | cGMP ↓ | Rhodopsin |
| Golf | Adenylyl cyclase (type III) | cAMP ↑ → CNG channel | Olfactory receptors |
Bacterial toxins as tools
| Toxin | Target | Chemistry | Consequence |
|---|---|---|---|
| Cholera toxin | Gsα | ADP-ribosylates an Arg, blocking GTP hydrolysis | Gs stays on; cAMP high; in intestinal cells, Cl⁻ and water secretion (watery diarrhoea) |
| Pertussis toxin | Giα (and Go, Gt) | ADP-ribosylates a Cys near the C-terminus, preventing receptor coupling | Gi stays off (GDP-bound); inhibition of adenylyl cyclase by Gi receptors is lost, so cAMP rises |
Both toxins raise cAMP, but by opposite logic: cholera toxin keeps a stimulator on, pertussis toxin removes a brake. A Part C stem that adds pertussis toxin and sees a hormone effect disappear is telling you the receptor uses Gi (or Go).
Desensitisation of GPCRs
- Homologous (only the stimulated receptor): GRKs (G-protein-coupled receptor kinases, for example β-adrenergic receptor kinase, GRK2) phosphorylate the agonist-occupied receptor; β-arrestin binds the phosphorylated tail, blocks G-protein coupling and recruits clathrin adaptors for endocytosis. The receptor is then recycled or degraded. Arrestins can themselves scaffold signalling (for example to MAP kinases).
- Heterologous (other receptors too): second-messenger kinases (PKA, PKC) phosphorylate receptors whether or not they are occupied.
- In rods, rhodopsin kinase and arrestin terminate photoexcited rhodopsin.
Second Messengers
cAMP and protein kinase A
- Adenylyl cyclase (a 12-transmembrane enzyme with two catalytic domains) converts ATP → cAMP + PPᵢ. Forskolin activates most isoforms directly, bypassing receptors and G proteins.
- cAMP phosphodiesterases hydrolyse cAMP → 5’-AMP. Caffeine, theophylline and IBMX inhibit PDEs, prolonging cAMP signals.
- PKA is an inactive tetramer R₂C₂. Each regulatory subunit binds two cAMP; binding of four cAMP releases two active catalytic subunits. PKA phosphorylates Ser/Thr in the motif Arg-Arg-X-Ser/Thr.
- Nuclear effect: C subunits enter the nucleus and phosphorylate CREB (cAMP-response-element-binding protein) on a Ser; phospho-CREB recruits the co-activator CBP/p300 and activates genes with a CRE in their promoters. This is how cAMP produces slow, transcriptional responses too.
- AKAPs (A-kinase anchoring proteins) tether PKA near its substrates. Epac is a cAMP-activated GEF for the small GTPase Rap1, a PKA-independent cAMP target. In olfactory neurons, cAMP opens cyclic-nucleotide-gated channels directly.
The glycogen cascade (liver and muscle).
graph LR
A["Adrenaline or glucagon"] --> R["GPCR"]
R --> G["Gs-alpha-GTP"]
G --> AC["Adenylyl cyclase"]
AC --> C["cAMP"]
C --> PKA["PKA"]
PKA --> PhK["Phosphorylase kinase
(also activated by Ca2+)"]
PhK --> GP["Glycogen phosphorylase
b to a"]
GP --> G1P["Glucose 1-phosphate"]
PKA -. "phosphorylates, inactivates" .-> GS["Glycogen synthase"]PKA simultaneously activates breakdown and inhibits synthesis, so the futile cycle is avoided. Each step is enzymatic, so the cascade amplifies the signal many thousand-fold.
The phosphoinositide pathway: IP₃, DAG and Ca²⁺
- PLCβ (activated by Gq) or PLCγ (activated by tyrosine phosphorylation via RTKs and antigen receptors) cleaves PI(4,5)P₂ into IP₃ (soluble) and DAG (stays in the membrane).
- IP₃ opens the IP₃ receptor, a Ca²⁺ channel in the ER membrane. Cytosolic Ca²⁺ rises from about 0.1 µM at rest to about 1 µM. The IP₃ receptor is also stimulated by moderate Ca²⁺ itself (calcium-induced calcium release), giving Ca²⁺ waves and oscillations; the frequency of oscillation can encode signal strength.
- DAG plus Ca²⁺ plus phosphatidylserine activates conventional PKC. Phorbol esters (tumour promoters) mimic DAG and activate PKC persistently. DAG can also be cleaved to release arachidonic acid (eicosanoid precursor).
- Store-operated Ca²⁺ entry: when ER Ca²⁺ falls, STIM1 in the ER membrane clusters and opens Orai1 channels in the plasma membrane, refilling stores and sustaining the signal (important in T cells).
- Recycling: IP₃ is dephosphorylated stepwise to inositol. Lithium inhibits inositol monophosphatase, depleting inositol and damping this pathway; this is one proposed basis of its action in bipolar disorder.
- Removal of Ca²⁺: SERCA pumps (into ER), plasma-membrane Ca²⁺-ATPase, Na⁺/Ca²⁺ exchanger, mitochondrial uptake.
Calmodulin is the main intracellular Ca²⁺ sensor: a small dumbbell protein with four EF-hand Ca²⁺ sites (two per lobe). Ca²⁺/calmodulin activates many targets:
| Target | What it does |
|---|---|
| CaM-kinase II | Multimeric Ser/Thr kinase; autophosphorylation keeps it active after Ca²⁺ falls (a molecular memory used in synaptic plasticity) |
| Calcineurin | Ca²⁺/calmodulin-activated phosphatase; dephosphorylates NFAT, which enters the nucleus (T-cell activation). Cyclosporin A (with cyclophilin) and FK506/tacrolimus (with FKBP12) inhibit calcineurin — immunosuppressants |
| Myosin light-chain kinase | Smooth muscle contraction |
| Phosphorylase kinase | Calmodulin is one of its subunits; links muscle contraction (Ca²⁺) to glycogen breakdown |
| Adenylyl cyclase and PDE isoforms; eNOS | Cross-talk between Ca²⁺ and cyclic nucleotides; NO production in endothelium |
cGMP and nitric oxide
| Source of cGMP | Activator | Example |
|---|---|---|
| Soluble guanylyl cyclase (cytosolic, haem-containing) | NO binding to the haem | Endothelial NO relaxes vascular smooth muscle; nitroglycerin releases NO |
| Receptor (particulate) guanylyl cyclase | Peptide ligand on a single-pass receptor | Atrial natriuretic peptide (ANP) on kidney and vessels |
- NO is made from arginine by NO synthase (giving citrulline). Endothelial NOS is activated by Ca²⁺/calmodulin, so acetylcholine acting on endothelium (Gq → Ca²⁺) makes NO that diffuses to the neighbouring smooth muscle. NO is short-lived and acts locally.
- cGMP activates PKG, which lowers smooth-muscle Ca²⁺ and relaxes it. PDE5 degrades cGMP; sildenafil inhibits PDE5.
- Phototransduction in rods is the reverse case: light lowers cGMP. Rhodopsin (11-cis-retinal → all-trans) → transducin (Gt) → PDE6 hydrolyses cGMP → cGMP-gated cation channels close → the “dark current” stops → rod hyperpolarises and releases less glutamate. One photoisomerised rhodopsin activates hundreds of transducins, which is why a rod can register a single photon. Full sensory detail is in Nervous System and Sense Organs.
Second-messenger summary
| Messenger | Made by | Destroyed or removed by | Main target |
|---|---|---|---|
| cAMP | Adenylyl cyclase (Gs↑, Gi↓) | cAMP PDE | PKA, Epac, CNG channels |
| cGMP | Soluble GC (NO), receptor GC (ANP) | PDE5, PDE6 | PKG, CNG channels |
| IP₃ | PLC (β via Gq, γ via tyrosine kinases) | Phosphatases | IP₃ receptor (ER Ca²⁺ release) |
| DAG | PLC | DAG kinase (→ phosphatidic acid), lipases | PKC |
| Ca²⁺ | Release from ER (IP₃R, ryanodine receptor), entry via channels | SERCA, PMCA, exchanger | Calmodulin, troponin C, PKC, synaptotagmin |
| PIP₃ | PI 3-kinase | PTEN (3-phosphatase), SHIP (5-phosphatase) | PH-domain proteins: Akt, PDK1, BTK |
Enzyme-Coupled Receptors
Receptor tyrosine kinases (RTKs)
RTKs (receptors for EGF, PDGF, FGF, NGF, insulin, VEGF and others) are single-pass receptors with a cytoplasmic tyrosine-kinase domain.
- Ligand-induced dimerisation (the insulin receptor is already a disulfide-linked α₂β₂ dimer; ligand changes its conformation).
- Trans-autophosphorylation: each kinase domain phosphorylates its partner, first in the activation loop (raising activity) and then on tyrosines in the tail.
- Docking: phosphotyrosines recruit proteins with SH2 or PTB domains (PLCγ, PI3K regulatory subunit p85, Grb2, Src, GAPs). Insulin receptor uses large docking proteins, IRS (insulin receptor substrates), which are tyrosine-phosphorylated in turn.
- Termination: receptor endocytosis and lysosomal degradation (ubiquitination by Cbl), and protein tyrosine phosphatases.
Modular domains to know: SH2 binds phosphotyrosine (with flanking residues for specificity); PTB also binds phosphotyrosine (NPXpY); SH3 binds proline-rich sequences; PH domains bind phosphoinositides (PIP₃); PDZ binds C-terminal peptides.
Ras and the MAP kinase cascade
graph LR
RTK["Active RTK
pTyr"] --> Grb2["Grb2
SH2 + SH3"]
Grb2 --> SOS["SOS
Ras-GEF"]
SOS --> Ras["Ras-GDP to Ras-GTP"]
Ras --> Raf["Raf
MAPKKK"]
Raf --> MEK["MEK
MAPKK, dual specificity"]
MEK --> ERK["ERK
MAPK, Thr and Tyr"]
ERK --> TF["Nucleus: Elk-1, Fos, Myc
immediate-early genes"]- Ras is a monomeric GTPase anchored to the plasma membrane by a farnesyl lipid. GEFs (SOS) turn it on; GAPs (p120 RasGAP, neurofibromin NF1) turn it off by accelerating its weak intrinsic GTPase.
- Oncogenic Ras (mutations at codons 12, 13 or 61) is GAP-resistant and stays GTP-bound. Loss of NF1 has a similar effect.
- MEK is a dual-specificity kinase: ERK needs phosphorylation on both a Thr and a Tyr in its activation loop (TEY motif). A three-kinase cascade gives amplification, switch-like responses and multiple control points; scaffold proteins (KSR in mammals, Ste5 in the yeast mating pathway) hold the kinases together and keep pathways that share components separate.
- Parallel MAPK modules (JNK, p38) respond to stress and cytokines.
PI 3-kinase and Akt
- Class I PI3K (recruited by its SH2-containing p85 subunit or by Ras) phosphorylates PI(4,5)P₂ at the 3-OH to make PI(3,4,5)P₃.
- PIP₃ recruits PH-domain proteins Akt (PKB) and PDK1 to the membrane. PDK1 phosphorylates Akt in its activation loop; mTORC2 phosphorylates a second site for full activity.
- Akt targets: inhibits BAD (pro-apoptotic) → survival; inhibits GSK3 → glycogen synthesis; inhibits FOXO transcription factors; activates mTORC1 (via TSC2) → protein synthesis and growth; in muscle and fat, drives GLUT4 translocation (insulin’s glucose uptake).
- PTEN removes the 3-phosphate and opposes the pathway; it is a tumour suppressor.
Cytokine receptors and JAK–STAT
Cytokine receptors (for interferons, many interleukins, erythropoietin, growth hormone, prolactin, leptin) have no kinase domain of their own. They are associated with JAKs (Janus kinases).
- Ligand brings receptor chains together; the JAKs cross-phosphorylate and activate.
- JAKs phosphorylate tyrosines on the receptor tails.
- STATs dock by their SH2 domains, are phosphorylated by JAKs, dissociate and dimerise through reciprocal SH2–phosphotyrosine contacts.
- STAT dimers enter the nucleus and activate genes.
- Negative feedback: STATs induce SOCS proteins that block JAKs or target receptors for degradation; tyrosine phosphatases (SHP-1) also terminate. Example: EPO → JAK2 → STAT5 in erythroid progenitors.
TGF-β receptors and Smads
The TGF-β superfamily (TGF-β, activins, BMPs, Nodal) signals through receptor serine/threonine kinases. Ligand binds the type II receptor, which phosphorylates and activates the type I receptor. Type I then phosphorylates R-Smads (Smad2/3 for TGF-β and activin; Smad1/5/8 for BMPs), which bind the co-Smad, Smad4, enter the nucleus and regulate genes with other transcription factors. I-Smads (Smad6, Smad7) inhibit. TGF-β is cytostatic for many epithelial cells (inducing CDK inhibitors), which is why tumours often lose this pathway.
Pathways that rely on regulated proteolysis
| Pathway | Off state | On state | Nuclear effector |
|---|---|---|---|
| Notch | Notch intact on membrane | Contact with Delta/Jagged on neighbour → cleavage by ADAM protease then γ-secretase | Notch intracellular domain (NICD) + CSL (RBPJ) → target genes. One receptor gives one signal; no amplification |
| Wnt/β-catenin | Destruction complex (APC, Axin, GSK3, CK1) phosphorylates β-catenin → ubiquitination → proteasome | Wnt binds Frizzled + LRP5/6 → Dishevelled → destruction complex inhibited | β-catenin + TCF/LEF |
| Hedgehog | Patched inhibits Smoothened; Gli/Ci processed to repressor | Hh binds Patched → Smoothened active (in vertebrates, accumulates in the primary cilium) | Full-length Gli/Ci activators |
| NF-κB | NF-κB held in cytoplasm by IκB | Signal (TNF, IL-1, TLRs) → IKK phosphorylates IκB → ubiquitination and degradation | NF-κB (p50/p65) |
These pathways recur in Developmental Biology and in the immune system.
Memory Tricks
Four cAMP free two C: PKA R₂C₂ needs four cAMP to release two catalytic subunits.
Don’t Confuse
| This | vs | That |
|---|---|---|
| Heterotrimeric G protein (Gαβγ, activated by GPCR as GEF) | vs | Monomeric GTPase (Ras, Rho, Rab, Ran; GEFs and GAPs are separate proteins) |
| GEF: swaps GDP for GTP, turns ON | vs | GAP: speeds GTP hydrolysis, turns OFF |
| Cholera toxin: Gsα stuck active | vs | Pertussis toxin: Giα stuck inactive |
| PLCβ: activated by Gq | vs | PLCγ: activated by tyrosine phosphorylation (RTKs, TCR, BCR) |
| Soluble GC: NO receptor | vs | Receptor GC: ANP receptor, single-pass |
| Rod response to light: cGMP falls, hyperpolarises | vs | Olfactory response to odour: cAMP rises, depolarises |
| Calcineurin: Ca²⁺/CaM-dependent phosphatase | vs | CaMKII: Ca²⁺/CaM-dependent kinase |
| Kd: occupancy half-maximal | vs | EC₅₀: response half-maximal; lower than Kd with spare receptors |
| Homologous desensitisation: GRK + arrestin, occupied receptor only | vs | Heterologous: PKA/PKC, other receptors too |
| Steroid receptor (GR): cytoplasmic, Hsp90-bound, homodimer | vs | Thyroid hormone receptor: nuclear, on DNA with co-repressor, RXR heterodimer |
Common Mistakes
Practice
All questions below are original practice questions written in CSIR NET style. They are not previous-year questions.
Level 1: Foundation
- Which enzyme makes IP₃ and DAG, and from which lipid?
- Which G-protein α subunit is the target of cholera toxin?
- Which domain binds PIP₃: SH2, SH3 or PH?
Answers
- Phospholipase C, from PI(4,5)P₂.
- Gsα.
- PH domain.
Level 2: Part B Style
Q1 (practice). A hormone binds its receptor with Kd = 2 nM. If the free hormone concentration is 6 nM, the fraction of receptors occupied is:
- (a) 25%
- (b) 33%
- (c) 67%
- (d) 75%
Answer and explanation
(d). θ = [L]/(Kd + [L]) = 6/(2 + 6) = 0.75. At three times Kd, three-quarters of the sites are filled.
Q2 (practice). A cell line’s response to hormone H is abolished by pre-treatment with pertussis toxin. The receptor for H most likely couples to:
- (a) Gs, raising cAMP
- (b) Gi/Go
- (c) Gq, raising IP₃
- (d) a receptor tyrosine kinase
Answer and explanation
(b). Pertussis toxin ADP-ribosylates Giα/Goα (and transducin) and uncouples them from receptors. Gs and Gq are not pertussis-toxin substrates, and RTKs do not use heterotrimeric G proteins.
Q3 (practice). Which pairing of drug and molecular action is incorrect?
- (a) Cyclosporin A — inhibits calcineurin with cyclophilin
- (b) Sildenafil — inhibits PDE5
- (c) Phorbol ester — mimics DAG and activates PKC
- (d) Lithium — activates adenylyl cyclase directly
Answer and explanation
(d). Lithium inhibits inositol monophosphatase (and other targets); the direct adenylyl cyclase activator is forskolin. The other three pairs are correct.
Q4 (practice). In a cell expressing a Ras mutant that cannot hydrolyse GTP, which manipulation would still block ERK activation by EGF?
- (a) Overexpressing SOS
- (b) A dominant-negative Grb2
- (c) A kinase-dead MEK
- (d) Removing EGF from the medium
Answer and explanation
(c). GTPase-dead Ras is constitutively active, so everything upstream of Ras (EGF, receptor, Grb2, SOS) no longer matters. Only a block downstream of Ras (Raf, MEK, ERK) stops the signal. This “constitutive mutant is epistatic to upstream components” logic is the core of Part C pathway-ordering questions.
Level 3: Part C Style
Q1 (practice). Membranes were incubated with increasing concentrations of a radiolabelled ligand and specific binding was measured. Two points on the Scatchard plot (bound/free against bound) were:
| Bound (fmol/mg protein) | Bound/Free (fmol mg⁻¹ nM⁻¹) |
|---|---|
| 100 | 200 |
| 300 | 100 |
(i) Calculate Kd and Bmax. (ii) What is the free ligand concentration at each point, and is the result consistent with the binding equation? (iii) What shape would the plot take if there were two classes of sites with different affinities?
Answer and worked solution
- Slope = (100 − 200)/(300 − 100) = −0.5 nM⁻¹ = −1/Kd → Kd = 2 nM. Extrapolating to B/F = 0: B = 100 + 200/0.5 = 500 fmol/mg = Bmax.
- Free = Bound ÷ (Bound/Free): 100/200 = 0.5 nM; 300/100 = 3 nM. Check with B = Bmax[L]/(Kd + [L]): 500 × 0.5/2.5 = 100 and 500 × 3/5 = 300. Both match.
- Curved, concave upward: a steep high-affinity segment at low B and a shallow low-affinity segment at high B. (Negative cooperativity gives a similar curve, so curvature alone does not distinguish the two.)
Q2 (practice). In isolated fat cells, a hormone binds its receptor with Kd = 1.0 nM, but half-maximal response (EC₅₀) is seen at 0.10 nM. An irreversible antagonist that inactivates 80% of the receptors shifts the dose–response curve to the right but does not lower the maximal response.
Which of the following are correct?
(A) At the EC₅₀, about 9% of receptors are occupied. (B) The cell has spare receptors. (C) The result shows the hormone is a partial agonist. (D) After the antagonist, the hormone concentration needed for half-maximal response will be higher than 0.10 nM.
- (a) A, B and D
- (b) A and C only
- (c) B and C only
- (d) B and D only
Answer and worked solution
(a) A, B and D.
- Occupancy at 0.10 nM = 0.10/(1.0 + 0.10) = 0.091, about 9%. (A) correct.
- A full response from a small fraction of receptors, and a maximum that survives loss of 80% of them, defines spare receptors. (B) correct.
- A partial agonist gives a lower maximum even at full occupancy; nothing here shows that. (C) wrong.
- With fewer receptors, more occupancy of the remainder is needed, so the curve shifts right and EC₅₀ rises. (D) correct.
Q3 (practice). Intestinal epithelial cells were treated as below and cAMP was measured (arbitrary units).
| Treatment | cAMP |
|---|---|
| None | 1 |
| Agonist X (acts on a Gs-coupled receptor) | 8 |
| Cholera toxin, 2 h | 25 |
| Cholera toxin, then agonist X | 25 |
| IBMX (PDE inhibitor) | 3 |
| Cholera toxin + IBMX | 60 |
Which interpretation is best?
- (a) Cholera toxin blocks the receptor for X.
- (b) Cholera toxin maximally activates Gs, so X adds nothing; cAMP is still degraded by PDEs, so blocking PDE raises it further.
- (c) Cholera toxin inhibits PDE.
- (d) Cholera toxin acts on Gi, so X is a Gi agonist.
Answer and worked solution
(b). Toxin alone gives more cAMP than the agonist and occludes it: the toxin has already locked Gs in the GTP-bound state, so the receptor has nothing more to activate. The further rise with IBMX shows the PDE is still working in toxin-treated cells, ruling out (c). (a) is unnecessary: occlusion arises downstream of the receptor. (d) is wrong: Gs, not Gi, is the cholera toxin target.
Quick Revision Table
| Item | Fact |
|---|---|
| Signalling modes | Endocrine, paracrine, autocrine, juxtacrine, synaptic |
| Occupancy | θ = [L]/(Kd + [L]); 50% at Kd, 75% at 3Kd, 90% at 9Kd |
| Scatchard | B/F vs B; slope −1/Kd; x-intercept Bmax |
| Nuclear receptors | Zinc-finger DBD + LBD; GR cytoplasmic with Hsp90; TR/RAR/VDR with RXR on DNA |
| GPCR | 7 TM; receptor = GEF for Gα; RGS = GAP |
| Gs / Gi / Gq / Gt | AC↑ / AC↓ + GIRK via Gβγ / PLCβ / PDE6 |
| Cholera / pertussis | Gsα Arg, GTPase blocked / Giα Cys, uncoupled — both raise cAMP |
| Desensitisation | GRK + β-arrestin (homologous); PKA/PKC (heterologous) |
| PKA | R₂C₂; 4 cAMP → 2 C; CREB at CRE |
| Forskolin / IBMX | Activates AC / inhibits PDE |
| PLC products | IP₃ (ER Ca²⁺ release) + DAG (PKC) |
| Calmodulin | 4 Ca²⁺, EF hands; CaMKII, calcineurin–NFAT, MLCK |
| cGMP | NO → soluble GC; ANP → receptor GC; PDE5 (sildenafil); rods: light lowers cGMP |
| RTK | Dimerise → autophosphorylate → SH2/PTB docking |
| Ras | GEF SOS on, GAP (NF1) off; codons 12, 13, 61 |
| MAPK | Raf → MEK (Thr + Tyr) → ERK |
| PI3K–Akt | PIP₃; PDK1; BAD, GSK3, FOXO, mTORC1; PTEN opposes |
| JAK–STAT | No intrinsic kinase; STAT SH2 dimerisation; SOCS feedback |
| TGF-β | Type II phosphorylates type I; R-Smad + Smad4 |
| Notch / Wnt / Hh / NF-κB | γ-secretase NICD / β-catenin stabilised / Patched releases Smoothened / IκB degraded |
Key Takeaways
What’s Next
- Two-Component Systems, Chemotaxis, Quorum Sensing and Light Signalling — the histidine-to-aspartate phosphorelays of bacteria and plants, and how plants read light.
- Adhesion, Junctions, ECM, Neurotransmission and Haematopoiesis — signals between touching cells and across synapses.
- Plant Hormones — auxin, gibberellin and other plant receptors built on regulated proteolysis.
- Quick Revision — the whole unit on one page.